Dopamine agonists in the treatment of Parkinson's disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review


Dopamine agonists are highly effective as adjunctive therapy to levodopa in advanced Parkinson's disease and have rapidly gained popularity as a monotherapy in the early stages of Parkinson's disease for patients less than 65-70 years old. In the latter case, dopamine agonists are about as effective as levodopa but patients demonstrate a lower tendency to develop motor complications. However, dopamine agonists lose efficacy over time and the number of patients remaining on agonist monotherapy decreases to less than 50% after 3 years of treatment. Thus, after a few years of treatment the majority of patients who started on dopamine agonists will be administered levodopa, in a combined dopaminergic therapy, in order to achieve a better control of motor symptoms.

Original languageEnglish
JournalExpert Review of Neurotherapeutics
Pages (from-to)81-89
Number of pages9
Publication statusPublished - 1 Jan 2006
Externally publishedYes

    Research areas

  • Dopamine agonists, Parkinson's disease, Pergolide, Pramipexole, Ropinirole, Rotigotine

See relations at Aarhus University Citationformats

ID: 139218360